All Life Sciences & Technology News
Top stories summarized by our editors
6/26/2019

Ascenda BioSciences, a clinical testing and diagnostics firm, has agreed to purchase fellow Alpharetta, Ga.-based firm Provista Diagnostics for an undisclosed amount. Provista has developed a range of blood-based diagnostic tests for early detection of women's cancers, including breast, endometrial, ovarian and HPV-related cancers.

Full Story:
FinSMEs
6/26/2019

European regulators granted CE mark approval to Avioq's VioOne HIV Profile Supplemental Assay, an enzyme-linked immunosorbent assay designed to confirm the presence of HIV-1 or HIV-2 antibodies in samples that were repeatedly reactive during diagnostic screening. Avioq is looking for partners to distribute the test in Europe.

Full Story:
FDAnews
More Summaries:
Avioq, EU
6/26/2019

A study in the journal Oecologia analyzed the link between food quantity and quality of Aedes aegypti mosquitoes and its capacity to become infected by the Zika virus and eventually transmit the disease to humans. Data showed that mosquitoes that were not fed with animal material had a higher likelihood for Zika virus infection and transmittal.

Full Story:
News Medical
6/26/2019

Chemotherapy and radiation help physicians save the lives of many children with cancer, but the treatments leave 30% of those survivors infertile. However, a technique developed through research in mice, pigs and monkeys -- and recently validated in macaques -- could preserve the fertility of these patients and is nearly ready for clinical testing in humans, writes researcher Kyle Orwig.

Full Story:
The Conversation (US)
6/26/2019

Scientists have developed a multi-organ system for testing cancer therapies using induced pluripotent stem cells, and they say the tool could someday reduce the need for animals in some research. The idea holds promise, according to Dr. Razelle Kurzrock of the University of California San Diego School of Medicine, but she said questions remain, and the concept should be seen as a "first step in the direction of a human 'avatar' model" rather than a fully validated technology.

6/25/2019

The partial hold imposed by the FDA in AbbVie's late-stage clinical trial for Venclexta/Venclyxto, or venetoclax, in combination with dexamethasone versus Celgene's Pomalyst, or pomalidomide, plus dexamethasone, in patients with translocation abnormality-positive relapsed or refractory multiple myeloma, has been lifted. AbbVie has made amendments to its trial protocol, including new measures on risk mitigation.

Full Story:
Seeking Alpha
6/25/2019

Senate health committee Chairman Lamar Alexander, R-Tenn., added new provisions to a bipartisan health care legislative package meant to lower health care costs. The Lower Health Care Costs Act would still create a benchmark for health insurer-provider payment disputes, but only for ancillary or emergency services, while it would raise the minimum age for purchasing tobacco products to 21 and prohibit brand-name drug companies from refusing to provide samples of medications to makers of generic drugs.

6/25/2019

CDC officials said that the number of confirmed measles cases in the US reached 1,077 across 28 states during the week of June 20, the highest number since 1992. Thirty of the 33 new cases reported last week were from New York.

More Summaries:
CDC
6/25/2019

The National Comprehensive Cancer Network is working with PatientPoint on point-of-care guidelines that will be placed in more than 4,000 oncology waiting rooms and back offices. "It is really important that we are able to put our resources at the point of care so that patients and providers are given evidence-based information that enables them to share in informed, shared decision-making," said C. Lyn Fitzgerald, senior vice president for US and global development with NCCN.

Full Story:
MM&M
6/25/2019

A video game called "Tumor Quest" is being used by Roche unit Genentech to educate patients about tumors. The game can be found on the company's website and is being promoted through social media channels.

Full Story:
FiercePharma
More Summaries:
Genentech, Roche